Article
Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Cancer - 1 Nov 2015
Menzies Alexander M, Wilmott James S, Drummond Martin, Lo Serigne, Lyle Megan, Chan Matthew M K, Thompson John F, Guminski Alex, Carlino Matteo S, Scolyer Richard A, Kefford Richard F, Long Georgina V
Abstract excerpt
BACKGROUND: The degree of response and the duration of survival of patients treated with mitogen-activated protein kinase (MAPK) inhibitors are highly variable. Whether baseline clinicopathologic factors can predict the clinical course with treatment is largely unknown. METHODS: For 142 consecutive immunotherapy- and MAPK inhibitor-naive patients with BRAF-mutant metastatic melanoma who were treated during...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.